1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone has been researched along with apomorphine in 2 studies
| Studies (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Trials (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Recent Studies (post-2010) (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 26 | 0 | 5 | 9,205 | 287 | 780 |
| Protein | Taxonomy | 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czachura, JF; Howbert, JJ; Rasmussen, K; Stockton, ME | 1 |
| Burger, JE; Czachura, JF; Gates, MR; Rasmussen, K | 1 |
2 other study(ies) available for 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and apomorphine
| Article | Year |
|---|---|
Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Cholecystokinin; Dopamine; Male; Mesencephalon; Neurons; Pyrazoles; Rats; Rats, Inbred Strains; Schizophrenia | 1991 |
The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Apomorphine; Benzodiazepines; Dose-Response Relationship, Drug; Hormone Antagonists; Male; Olanzapine; Pirenzepine; Pyrazoles; Rats; Reflex, Startle | 1997 |